ArticleCancer innovation2024

Synergistic effect of additional anlotinib and immunotherapy as second-line or later-line treatment in pancreatic cancer: A retrospective cohort study.

Boyu Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.